Psoriasis vulgaris is a chronic relapsing and remitting inflammatory skin disease that affects 0.5-11.43% of the population worldwide.
Psoriasis vulgaris is a chronic relapsing and remitting inflammatory skin disease that affects 0.5-11.43% of the population worldwide. 1 Psoriasis negatively impacts patients' quality of life. 2, 3 For many patients, improved quality of life is as important as objective clinical improvement of psoriasis lesions. 4 Many different tools have been created to evaluate the effect of chronic skin conditions on quality of life (e.g. Dermatology Life Quality Index, Skindex, SF-36, among others). The Dermatology Life Quality Index (DLQI) was first reported in 1994 and is a validated tool used to assess the effect of dermatologic conditions on quality of life. 5, 6 It is the most commonly used quality of life Biologic therapy can lead to improvements in quality of life that are both statistically significant and clinically significant as seen when the banding concept of DLQI scores is applied. 11 Thus, improving quality of life in patients with psoriasis should be of the utmost importance to clinicians. There are a variety of treatment options for moderate to severe plaque psoriasis and biologics have revolutionized the management of this disease. For patients with psoriasis treated with biologic therapy, there is a clear correlation between DLQI and PASI scores. 12 At the time of writing this manuscript, six biologic medications were approved by the United States Food and Drug administration (FDA) for use in plaque psoriasis: adalimumab, etanercept, infliximab, ixekizumab, secukinumab, and ustekinumab. The use of these biologics for psoriasis is supported by data from randomized clinical trials (RCTs). Other reviews have examined the effect of biologic therapy on quality of life. 13, 14 However, new drugs have been approved since the prior studies were published and many of the originally approved drugs have been withdrawn from the market. This review presents an updated assessment of quality of life studies in psoriasis.
Data Sources:
We searched four computerized bibliographical databases for articles published since inception to August 2016: Pubmed, Cochrane Library CENTRAL, Ovid MEDLINE, and Embase. Search terms included:
"Quality of Life," "DLQI," "Dermatology Life Quality Index," "Dermatology quality of life index," "psoriasis," "randomized controlled trials," "biologic therapy," "biologic," and the generic names for each of the drugs. The search was restricted to publications in English. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Prospero registration no. CRD42016046523). The search strategy used is given in Appendix 1. We reviewed trial registers (clinicaltrials.gov) and searched grey literature. Reference lists of all included studies and of recent reviews were also assessed. Electronic publications in advance of print were also included.
Inclusion Criteria:
We included double-blind, RCTs of patients with plaque psoriasis treated with FDA approved biologic treatments that measured DLQI at baseline and endpoint in adults (aged >18 years).
Exclusion Criteria:
The exclusion criteria were as follows: trials that included only a subtype of psoriasis, trials that only randomized patients with
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concomitant psoriatic arthritis, studies that included any patient less than 18 years of age, articles where the change in DLQI values from baseline to endpoint could either not be reliably calculated or could not be obtained after requesting additional information from the author or study sponsor, and abstracts and posters where further data were not available upon contacting the author.
Outcome measures:
The primary outcome recorded was the mean DLQI score at baseline and endpoint. For studies with an open-label extension, the data were extracted only for the period of the study while it was randomized and controlled. For crossover trials, the data were extracted prior to the crossover.
Data extraction and synthesis:
One reviewer (G.P.) extracted data, another reviewer (A.N.) checked the extracted data for accuracy, and the reviewers met to discuss any disagreements.
We created and piloted a data collection form for recording study design, DLQI scores, drug administered, dosing schedule, and quality of the methodology. Risk of bias was assessed using the Cochrane risk of bias tool independently by 2 reviewers (G.P. and A.N.). Disagreements were resolved by discussion.
After screening 571 records, we identified 34 RCTs enrolling a total of 16,784 patients published between December 2003 and May 2016 that fit our inclusion and exclusion criteria. For these studies, 38 articles were retrieved, including those related to the original RCT publication as well as subanalyses of the original RCT. Of the 34 original RCTs included, complete data, meaning baseline and final mean DLQI scores, was retrieved for 24 studies (70.6%). Of these 24 studies, 66.7% present unpublished data obtained from study authors and sponsors after contacting them for additional information.
The mean DLQI at baseline was reported in 79.4% of studies (Table 1) . The median at baseline was reported in 14.7% of the studies. The mean DLQI at endpoint was only reported in 23.5% of studies and the median DLQI at endpoint was reported in 5.9% of studies. The mean change in DLQI was reported in 64.7% of studies.
Adalimumab. There were five RCTs comprising 1,918 patients that assessed DLQI data in patients treated with adalimumab. Of these studies, we obtained complete data for four RCTs (80%). The DLQI for the placebo group ranged from 8.4-14.6 at baseline and 7.6-12.3 at endpoint. For those treated with adalimumab, the mean DLQI ranged from 8.4-14.6 at baseline and 2.0-5.0 at endpoint.
Etanercept. There were eight RCTs comprising 2,968 patients that assessed DLQI data in patients treated with etanercept. Of these studies, we obtained complete data for four RCTs (50%). The DLQI for the placebo group ranged from 12.2-14 at baseline and 9.75-12.3 at endpoint. For those treated with etanercept, the mean DLQI ranged from 10-13.87 at baseline and 3.8-5.8 at endpoint.
Infliximab. There were five RCTs comprising 1,639 patients that assessed DLQI data in patients treated with infliximab. Of these studies, we obtained complete data for four RCTs (80%). The DLQI for the placebo group ranged 10.5-14.4 at baseline and 11.2-13.1 at endpoint. For those treated with infliximab, the mean DLQI ranged from Ixekizumab. There were four RCTs comprising 4,008 patients that assessed DLQI data in patients treated with ixekizumab. Of these studies, we obtained complete data for all 4 RCTs (100%). The DLQI for the placebo group ranged from 10.81-12.8 at baseline and 10.26-11.6 at endpoint. For those treated with ixekizumab, the mean DLQI ranged from 10.36-13.4 at baseline and 1.9-4.66 at endpoint.
Secukinumab. There were five RCTs comprising 3,294 patients that assessed DLQI data in patients treated with secukinumab. Of these studies, we obtained complete data for 2 RCTs (40%). The DLQI for the placebo group ranged from 12.0-13.4 at baseline and 10.9-11.5 at endpoint. For those treated with secukinumab, the mean DLQI ranged from 11.3-13.9 at baseline and 2.5-3.7 at endpoint.
Ustekinumab. There were seven RCTs comprising 2,957 patients that assessed DLQI data in patients treated with ustekinumab. Of these studies, we obtained complete data for 6 RCTs (85.7%). The DLQI for the placebo group ranged from 10.5-15.2 at baseline and 9.7-14.7 at endpoint.
For those treated with ustekinumab, the mean DLQI ranged from 10.5-16.1 at baseline and 2.1-4.8 at endpoint.
Quality of Evidence for Included Studies.
Appendix 2 provides an assessment of the risk of bias for the included studies. All studies were randomized controlled trials. Most studies limited the bias inherent to the trial by employing the use of random sequence generation, allocation concealment, and blinding of participants, personnel, and assessors. The first generation of biologic therapies for plaque psoriasis were the TNF-alpha inhibitors (adalimumab, etanercept, and infliximab). More recently, the targeted therapies against interleukin (IL)-17 and IL-12/23 have heralded a new era of biologic therapies. Although there were slight differences between the endpoint scores for the TNF-alpha inhibitors and the newer biologics, it is not clear whether these slight differences correspond to clinically significant differences in quality of life. Comparing the ranges of DLQI scores reported across the different drugs, most patients reported a "small effect" of their psoriasis symptoms on quality of life after treatment.
When discussing improvement in quality of life, it is important to keep in mind the concept of minimal clinically important difference (MCID). MCID is defined as "the smallest difference in score in the domain of interest which patients perceive as beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient's management." 21 Taken from the patient's perspective, this may mean a significant improvement in quality of life and symptomatology; while taken from the clinician's perspective, this may mean a significant improvement in the treatment or prognosis of the disease. Several studies using different methodologies have attempted to determine the minimum clinically important change in DLQI score and results have ranged from 3-5. 22 Four studies included in this review reported some measure of patients who achieved a meaningful decrease in DLQI (either number or percentage of patients).
It is possible that the DLQI may not be the best quality of life metric for patients with psoriasis. The DLQI is a scale used to objectively quantify the effect of dermatologic conditions on quality of life. It was surprising to note that there were no significant differences in DLQI scores among the different biologic drugs. Most biologic drugs achieved a final DLQI of 2-5 after starting at a baseline of 8-14. The most recent clinical trials tout major differences in PASI scores as evidence for the efficacy of certain drugs over others. This difference in efficacy was not evident when looking at DLQI in isolation. The DLQI instrument as a measure of quality of life may not be DISCUSSION sensitive enough to detect minor improvements attributable to increased skin clearance and then translate these improvements to effects on quality of life.
Considering the minor differences in final DLQI scores among the different medications, it is important to keep in mind economic costs when prescribing a biologic therapy. The annual costs of these drugs range from $30,001 for infliximab to $69,762 for ixekizumab. 23 Older TNF-alpha inhibitors such as adalimumab and etanercept are less expensive than the newer specific IL inhibitors. There are limited healthcare resources available and many patients struggle to afford their medications, therefore it is reasonable to utilize more affordable medications given the comparable effects on quality of life. A recent meta-analysis found no difference in risk of serious infections among different biologic therapies. 24 However, newer medications offer less frequent dosing schedules, which can also augment perceived quality of life for patients.
Our systematic review was extensive with a precisely executed search strategy and selection process. It serves as an up to date resource for quality of life data in clinical trials of psoriasis. The last similar review was published in 2006 with several drugs that are not currently available in the U.S. 13 Additionally, the studies included in our review were all randomized controlled trials that are less susceptible to sources of bias.
Our systematic review has some limitations. First, there was significant heterogeneity among the included studies in terms of length of study, characteristics of enrolled patients, and biologic therapy protocol. These studies were conducted with different objectives and comparison treatments across different trials. Although we originally planned to conduct a meta-analysis that would allow us to combine the results across several trials for each drug and thus compare drugs to one another, this proved to be impossible due to significant heterogeneity. Since we were unable to conduct the meta-analysis, it is not clear which drug is the most effective at improving quality of life. Future studies should determine whether clinically significant differences in quality of life (keeping in mind efficacy and cost-effectiveness) exist between the studied drugs.
Second, most studies did not uniformly report DLQI data. In these cases, significant efforts were made to contact study authors and sponsoring companies for additional information. Many complied with our requests for further information. However, several study sponsors declined to provide unpublished data for use in this study. Poor reporting of quality of life data continues to be a significant problem in dermatology research 25 and others have had similar experiences in which a lack of reporting guidelines for quality of life data resulted in data analysis difficulties. 
